Kidney Protection Using the RenalGuard® System in Cardiac Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-31

Study Completion Date

2019-09-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective randomised control trial 1:1 in patients at risk of developing Acute Kidney Injury after cardiac surgery comparing the RenalGuard® System to current medical treatment. 110 patients will be recruited for each group. The aim of the study is to assess whether the RenalGuard® system reduces Acute Kidney Injury (AKI) after cardiac surgery as compared to current practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI

NCT06811805

AKI - Acute Kidney Injury Cardiac Surgery Associated - Acute Kidney Injury

ACTIVE_NOT_RECRUITING NA

Safety & Efficacy of RenalGuard® Therapy in the Prevention of Cardiac Surgery Associated Acute Kidney Injury

NCT07123935

Cardiac Surgery Associated - Acute Kidney Injury AKI - Acute Kidney Injury

NOT_YET_RECRUITING NA

Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI

NCT02793661

Cardiovascular Disease Acute Kidney Injury

UNKNOWN NA

Cost-effectiveness Analyses for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery in the UK

NCT07108634

Acute Kidney Injury

NOT_YET_RECRUITING

GUARD-AKI: Validation of AKI-Sapere in Cardiac Surgery Patients

NCT03635606

Coronary Artery Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients undergoing elective or in-house urgent cardiac surgery will be approached for the KIDNEY study if they fulfil the inclusion criteria. Upon consent pre-operative blood tests will be as per the usual practice. Moreover, 2ml of the serum will be stored for NGAL analysis.

Following the consenting process, patients will be randomised (envelop- based) into either having the RenalGuard® System (Study group) or current medical management (Control group).

Study group:

Patients in the study group will have the RenalGuard® System started in anaesthetic room once the peripheral line and arterial lines are sited. The RenalGuard® System will continue to run throughout the cardiac procedure in the operating room and up to 6 hours post-op after the patient has been transferred to the unit. Patients will be managed at a zero balance i.e. volume of the urine output will be matched to the volume of Hartmann's fluid infusion. Forced diuresis is then initiated.

Control group:

Patients in the control group will be managed as per current medical practice which will include no forced diuresis in operating room and the use of inotropes for maintenance of mean arterial pressure and intravenous furosemide for diuresis.

An additional blood test (NGAL) at six hours post-op will be taken and would require 2mls of blood. The NGAL specimens will be dealt with by the biochemistry lab (centrifuged \& stored) so that the specimens can be analysed in batches.

Patients kidney function (U\&Es) will be tested at the time of post-operatively as per usual practice (Day1, pre-discharge and as clinically indicated) and at the post-operative surgical out-patient visit.

Pre-operative, intra-operative and post-operative data will be collected for each patient group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Renal Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Patients will receive the RenalGuard system

Group Type EXPERIMENTAL

RenalGuard

Intervention Type DEVICE

Control group

Standard practice will be performed with no RenalGuard system

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RenalGuard

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients undergoing surgery (elective or in-house urgent)
2. Patient 18 years old and over
3. Patient able to give written consent
4. Patient at risk of developing AKI after cardiac surgery (at least one factor)

1. Diabetics (IDDM or NIDDM) with normal kidney function pre-op
2. Patients with eGFR 20-60
3. Patients undergoing combined cardiac procedures when the CPB time is likely to exceed 120 minutes
4. Patients with Hb of 12.5 g/dl or below
5. Logistic Euroscore of 5 and above
5. Patient not involved with another study

Exclusion Criteria

1. Emergency surgery
2. Patient unable to give written consent
3. Patient already dialysis dependent or eGFR \<20
4. Patient partaking in another study
5. Pregnant patients

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No